Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

University Hospital, Caen2,336 enrolled

Overview

Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients receiving PARPi may experience rare but serious (or not) adverse events such as hypertension whose data are scarce. The objective was to investigate reports of hypertension related to PARPi, including olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, and fluzoparib using the World Health Organization's (WHO) pharmacovigilance database: VigiBase.

Here, investigators use the World Health Organization's (WHO) database of individual safety case reports, to identify cases of hypertension AE related to PARPi.

Study Type

OBSERVATIONAL

Enrollment

2,336

Conditions

Cancer

Interventions

olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparibDRUG

All patients treated at least with 1 PARPi (alone or in combination)

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * case reported in the World Health Organization (WHO) database (VigiBase) of individual safety case reports at the time of the extraction, * patients treated with at least 1 PARPi (with ATC classification system): olaparib (ATC L01XX46), niraparib (ATC L01XX54), rucaparib (ATC L01XX55), talazoparib (ATC L01XX60), veliparib, pamiparib, fluzoparib (none). Exclusion Criteria: -chronology not compatible between the PARPi and adverse event

Locations (1)

Alexandre Joachim

Caen, Basse Normandie, France

Outcomes

Primary Outcomes

hypertension reports related to PARPi.

Identification of the hypertension adverse event related to PARP inhibitors reported in the World Health Organization's (WHO) database of individual safety case reports.

Time frame: From inception to 16 Feb, 2023

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.